The roles of EPS-R1-induced CCR6+ CD8+ T cells may differ, potentially relying on tumor heterogeneity, the time and duration of ICB therapy, the content and variety of cytokines/chemokines within the tumors and other intratumoral immune cells. This evidence concerns the gene CCR6 and neoplasm.